AVDL Avadel Pharmaceuticals plc
USHealthcareAs of 2026-02-13 09:30
Why AVDL matters now
Avadel Pharmaceuticals plc (AVDL) is a US stock in Healthcare. The latest InvestLog snapshot shows $21.64 with +0.00% on the session and $2.12B in market capitalization; recent performance reads 1-month +0.00% and YTD +0.56%.
The latest financial table shown here is Q3 2025, with revenue of $77.5M, net income of $20.0K, and EPS of $0.00. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 1.7%.
The latest indexable market news headline is "Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Hold with a median target of $20.00; recent insider activity includes Weiss Asset Management LP filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
21.39
P/S
8.55
EV/EBITDA
205.49
DCF Value
$12.00
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.5%
Operating Margin
1.8%
Net Margin
-0.1%
ROE
-0.3%
ROA
-0.1%
ROIC
0.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $77.5M | $20.0K | $0.00 |
| Q2 2025 | $68.1M | $9.7M | $0.10 |
| Q1 2025 | $52.5M | $-4.9M | $-0.05 |
| Q4 2024 | $50.4M | $-5.0M | $-0.05 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$21.43
Target (Median)
$20.00
Target Range
$18.50 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
IE
Exchange
—
Beta
1.31
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.